Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer

Immune checkpoint inhibitors (ICIs) have profoundly changed the therapeutic landscape and outcome of many solid tumours [1,2]. In metastatic colorectal cancer (mCRC), however, ICIs are effective only for the small group (about 5%) of patients with mismatch repair deficient (dMMR)/high microsatellite instable (MSI-H) tumours [3,4]. Pembrolizumab, and nivolumab (+/- ipilimumab) were first approved by international regulatory authorities, based on the impressive results of nonrandomised studies conducted in this patient population [5 –7].
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Source Type: research